The FDA has granted accelerated approval to teclistamab-cqyv (Tecvayli®, Janssen Biotech) for adult patients with relapsed/refractory multiple myeloma previously treated with four or more lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. Teclistimab is the first bispecific B-cell maturation antigen (BCMA)–directed CD3 T-cell engager. "Standard treatment of multiple myeloma includes the administration of immunomodulatory agents, p...

At the 47th Annual Oncology Nursing Society (ONS) Congress in Anaheim, California, Charise Gleason, Advanced Practice Provider Chief at Emory University Winship Cancer Institute, spoke about the current role of B-cell maturation antigen (BCMA)–directed therapeutic approaches in the multiple myeloma treatment landscape. In this interview with Oncology Data Advisor, she delves further into the mechanisms of action of antibody-drug conjugates, chimeric antigen receptor (CAR) T-cell therapies, and b...

​With a five-year survival rate of only 50.7%, multiple myeloma remains difficult to treat. In this interview with i3 Health, Carol Ann Huff, MD, Medical Director for the Johns Hopkins Kimmel Cancer Center, explores the challenges and research advances of myeloma treatment. She also gives advice on helping patients to find assistance with the prohibitive costs of treatment and on handling the difficulties involved in treating patients at smaller community cancer centers, including patients who l...